XML 17 R3.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Income Statements - EUR (€)
€ in Millions, shares in Millions
 6 Months Ended 12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Profit (loss) [abstract]      
Net sales € 20,187 € 19,790 € 42,997
Other revenues 1,358 1,005 2,392
Cost of sales (6,347) (6,130) (13,695)
Gross profit 15,198 14,665 31,694
Research and development expenses (3,193) (3,147) (6,706)
Selling and general expenses (5,182) (4,953) (10,492)
Other operating income 617 416 1,969
Other operating expenses (1,422) (1,204) (2,531)
Amortization of intangible assets (1,035) (910) (2,053)
Impairment of intangible assets (15) (87) 454
Fair value remeasurement of contingent consideration (26) (17) 27
Restructuring costs and similar items (547) (792) (1,336)
Other gains and losses, and litigation (73) (142) (370)
Operating income 4,322 3,829 10,656
Financial expenses (370) (189) (440)
Financial income 286 34 206
Income before tax and investments accounted for using the equity method 4,238 3,674 10,422
Income tax expense (730) (495) (2,006)
Share of profit/(loss) from investments accounted for using the equity method (52) 58 68
Net income 3,456 3,237 8,484
Net income attributable to non-controlling interests 26 53 113
Net income attributable to equity holders of Sanofi € 3,430 € 3,184 € 8,371
Average number of shares outstanding (in shares) 1,249.9 1,250.0 1,251.9
Average number of shares after dilution (in shares) 1,254.5 1,255.3 1,256.9
Basic earnings per share (in euros per share) € 2.74 € 2.55 € 6.69
Diluted earnings per share (in euros per share) € 2.73 € 2.54 € 6.66